BMRA · Biomerica Inc
$2.31
+0.09 (+4.05%)
At close · Sep 4
Going-concern doubt
— flagged Aug 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern. Our future viability depends on the successful execution of our strategic plans, securing additional financing, and achieving profitable operations.”View the 10-K filed Aug 31, 2026
Market Cap
$10.10M
Shares
4.59M
BMRA metrics
63 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$2.22
Market cap
$10.10M
Price action
19 metricsPrice change (1W)
+5.7%
Price change (30D)
+37.0%
Price change (3M)
+3.3%
Price change (6M)
+12.7%
Price change (YTD)
-11.9%
Price change (1Y)
-22.1%
Trailing year
Price change (5Y)
—
52-week high
$3.20
52-week low
$1.49
Change from 52-week high
-30.6%
Change from 52-week low
+49.0%
Annualized volatility
55.4%
Beta
0.8
RSI (14D)
74.2
Price vs SMA 50
+30.8%
Price vs SMA 200
+4.5%
Avg volume (3M)
66,054
Relative volume
0.9
Average dollar volume
$136,165
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
4.59M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.3×
reciprocal yield 44.1%
P / book
3.8
reciprocal yield 26.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-37.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
8.1%
Operating margin
-119.5%
Trailing 12 months
Net margin
-84.8%
Gross profit (TTM)
$362,000
Operating profit (TTM)
−$5.32M
Net income (TTM)
−$3.77M
Trailing 12 months
Diluted EPS (TTM)
$-1.30
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+17.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.5%
Year over year · more shares
Revenue CAGR (3Y)
-5.9%
Revenue CAGR (5Y)
-9.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-143.5%
Return on assets
-55.9%
Debt / equity
—
Current ratio
1.6
EBITDA (TTM)
−$5.24M
Free cash flow (TTM)
—
Quick ratio
0.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.31M
Latest balance sheet
Cash & equivalents
$1.31M
Total assets
$6.76M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$3.42M
Capital expenditures (TTM)
$51,000
R&D (TTM)
$788,000
SG&A (TTM)
$4.89M
Stock compensation (TTM)
$476,000
R&D / revenue
17.7%
Stock compensation / revenue
10.7%
Ownership (13F)
3 metrics13F filers
20
13F filer change QoQ
+9
Institutional ownership
2.7%
Short interest
3 metricsShort interest
0.4%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
44 / 100
Insider activity
2 metricsNet insider buying (90D)
$158,000
Insider-sentiment score
93 / 100
Risk flags
1 metricsGoing concern
Flagged